287 related articles for article (PubMed ID: 27847095)
1. Proteomic analysis and translational perspective of hepatocellular carcinoma: Identification of diagnostic protein biomarkers by an onco-proteogenomics approach.
Chiou SH; Lee KT
Kaohsiung J Med Sci; 2016 Nov; 32(11):535-544. PubMed ID: 27847095
[TBL] [Abstract][Full Text] [Related]
2. Onco-proteogenomics identifies urinary S100A9 and GRN as potential combinatorial biomarkers for early diagnosis of hepatocellular carcinoma.
Huang CH; Kuo CJ; Liang SS; Chi SW; Hsi E; Chen CC; Lee KT; Chiou SH
BBA Clin; 2015 Jun; 3():205-13. PubMed ID: 26675302
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for the early diagnosis of hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Saito K; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Oct; 21(37):10573-83. PubMed ID: 26457017
[TBL] [Abstract][Full Text] [Related]
4. Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics.
Masuda T; Miyoshi E
Clin Chem Lab Med; 2011 Jun; 49(6):959-66. PubMed ID: 21428856
[TBL] [Abstract][Full Text] [Related]
5. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review.
Kimhofer T; Fye H; Taylor-Robinson S; Thursz M; Holmes E
Br J Cancer; 2015 Mar; 112(7):1141-56. PubMed ID: 25826224
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs as biomarkers for hepatocellular carcinoma diagnosis and prognosis.
He S; Zhang DC; Wei C
Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):426-34. PubMed ID: 25746139
[TBL] [Abstract][Full Text] [Related]
7. A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors.
Reis H; Pütter C; Megger DA; Bracht T; Weber F; Hoffmann AC; Bertram S; Wohlschläger J; Hagemann S; Eisenacher M; Scherag A; Schlaak JF; Canbay A; Meyer HE; Sitek B; Baba HA
Biochim Biophys Acta; 2015 Jun; 1854(6):641-50. PubMed ID: 25448011
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis of HBV-associated HCC: insights on mechanisms of disease onset and biomarker discovery.
Niu D; Feng H; Chen WN
J Proteomics; 2010 May; 73(7):1283-90. PubMed ID: 20188222
[TBL] [Abstract][Full Text] [Related]
9. Proteomics for the early detection and treatment of hepatocellular carcinoma.
Feng JT; Shang S; Beretta L
Oncogene; 2006 Jun; 25(27):3810-7. PubMed ID: 16799622
[TBL] [Abstract][Full Text] [Related]
10. Proteomics in the diagnosis of hepatocellular carcinoma: focus on high risk hepatitis B and C patients.
El-Aneed A; Banoub J
Anticancer Res; 2006; 26(5A):3293-300. PubMed ID: 17094443
[TBL] [Abstract][Full Text] [Related]
11. TMT-HCC: a tool for text mining the biomedical literature for hepatocellular carcinoma (HCC) biomarkers identification.
Abul Seoud RA; Mabrouk MS
Comput Methods Programs Biomed; 2013 Dec; 112(3):640-8. PubMed ID: 23978553
[TBL] [Abstract][Full Text] [Related]
12. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma.
Orimo T; Ojima H; Hiraoka N; Saito S; Kosuge T; Kakisaka T; Yokoo H; Nakanishi K; Kamiyama T; Todo S; Hirohashi S; Kondo T
Hepatology; 2008 Dec; 48(6):1851-63. PubMed ID: 18937283
[TBL] [Abstract][Full Text] [Related]
13. Proteogenomics for understanding oncology: recent advances and future prospects.
Subbannayya Y; Pinto SM; Gowda H; Prasad TS
Expert Rev Proteomics; 2016; 13(3):297-308. PubMed ID: 26697917
[TBL] [Abstract][Full Text] [Related]
14. A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma.
Ahn YH; Shin PM; Oh NR; Park GW; Kim H; Yoo JS
J Proteomics; 2012 Sep; 75(17):5507-15. PubMed ID: 22789673
[TBL] [Abstract][Full Text] [Related]
15. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma.
Wang X; Zhang A; Sun H
Hepatology; 2013 May; 57(5):2072-7. PubMed ID: 23150189
[TBL] [Abstract][Full Text] [Related]
16. New perspectives and strategy research biomarkers for hepatocellular carcinoma.
Saffroy R; Pham P; Reffas M; Takka M; Lemoine A; Debuire B
Clin Chem Lab Med; 2007; 45(9):1169-79. PubMed ID: 17635075
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of primary hepatocellular carcinoma with single and multiple lesions by iTRAQ-based quantitative proteomics.
Xing X; Huang Y; Wang S; Chi M; Zeng Y; Chen L; Li L; Zeng J; Lin M; Han X; Liu X; Liu J
J Proteomics; 2015 Oct; 128():262-71. PubMed ID: 26300425
[TBL] [Abstract][Full Text] [Related]
18. Integrated proteo-genomic approach for early diagnosis and prognosis of cancer.
Shukla HD; Mahmood J; Vujaskovic Z
Cancer Lett; 2015 Dec; 369(1):28-36. PubMed ID: 26276717
[TBL] [Abstract][Full Text] [Related]
19. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.
Song PP; Xia JF; Inagaki Y; Hasegawa K; Sakamoto Y; Kokudo N; Tang W
World J Gastroenterol; 2016 Jan; 22(1):262-74. PubMed ID: 26755875
[TBL] [Abstract][Full Text] [Related]
20. Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma.
Sun Y; Mi W; Cai J; Ying W; Liu F; Lu H; Qiao Y; Jia W; Bi X; Lu N; Liu S; Qian X; Zhao X
J Proteome Res; 2008 Sep; 7(9):3847-59. PubMed ID: 18646787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
